TherapeuticsMD Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited - in thousands)
Three and Nine Months Ended September 30, 2024
| Common Stock · Additional Paid in · Accumulated | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Total | |
| Balance, January 1, 2024 | 11,532 | $11 | $978,917 | $(949,641) | $29,287 |
| Share-based compensation | — | — | 111 | — | 111 |
| Net loss | — | — | — | (734) | (734) |
| Balance, March 31, 2024 | 11,532 | $11 | $979,028 | $(950,375) | $28,664 |
| Share-based compensation | — | — | 96 | — | 96 |
| Net loss | — | — | — | (1,090) | (1,090) |
| Balance, June 30, 2024 | 11,532 | $11 | $979,124 | $(951,465) | $27,670 |
| Share-based compensation | — | — | 33 | — | 33 |
| Net loss | — | — | — | (609) | (609) |
| Balance, September 30, 2024 | 11,532 | $11 | $979,157 | $(952,074) | $27,094 |
Three and Nine Months Ended September 30, 2023
| Common Stock · Additional Paid in · Accumulated | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Total | |
| Balance, January 1, 2023 | 9,498 | $9 | $974,497 | $(939,363) | $35,143 |
| Shares issued for vested restricted stock units | 455 | 1 | - | - | 1 |
| Share-based compensation | - | - | 483 | - | 483 |
| Net loss | - | - | - | (3,603) | (3,603) |
| Balance, March 31, 2023 | 9,953 | $10 | $974,980 | $(942,966) | $32,024 |
| Shares issued for vested restricted stock units | 60 | - | - | - | - |
| Shares issued for sale of common stock related to private placement sale | 313 | 1 | 1,149 | - | 1,150 |
| Share-based compensation | - | - | 437 | - | 437 |
| Shares issued for exercise of warrants | 249 | - | - | - | - |
| Net loss | - | - | - | (2,414) | (2,414) |
| Balance, June 30, 2023 | 10,575 | $11 | $976,566 | $(945,380) | $31,197 |
| Share-based compensation | - | - | 233 | - | 233 |
| Net loss | - | - | - | (3,378) | (3,378) |
| Balance, September 30, 2023 | 10,575 | $11 | $976,799 | $(948,758) | $28,052 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.